EP10-A3 Vol. 26 No. 34 Replaces EP10-A2 Vol. 22 No. 29

Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline—Third Edition

This guideline provides experimental design and data analysis for preliminary evaluation of the performance of a measurement procedure or device.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.



Clinical and Laboratory Standards Institute

Advancing Quality in Healthcare Testing

The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. Our process is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

A document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The CLSI voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most documents are subject to two levels of consensus— "proposed" and "approved." Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

Proposed A consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Approved An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

Our standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following CLSI's established consensus procedures. Provisions in CLSI standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any document. Address comments to Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in CLSI projects. Please contact us at customerservice@clsi.org or +610.688.0100 for additional information on committee participation.

Volume 26 Number 34

EP10-A3 ISBN 1-56238-622-0 ISSN 0273-3099

Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline—Third Edition

Jan S. Krouwer, PhD George S. Cembrowski, MD, PhD Daniel W. Tholen, MS

Abstract

Clinical and Laboratory Standards Institute document EP10-A3—*Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline—Third Edition* is intended to facilitate a limited, preliminary evaluation of the performance of a measurement procedure or device. Using the experimental design and data analysis procedure described, determination of whether a device has problems that require further evaluation or referral to the manufacturer can be done with a minimum expenditure of time and material. Included in Appendixes A and B are sample data sheets that should facilitate the analysis of the data. Appendix C contains a more sophisticated, powerful, statistical method for determining the possible causes of imprecision.

Clinical and Laboratory Standards Institute (CLSI). Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline—Third Edition. CLSI document EP10-A3 (ISBN 1-56238-622-0). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI/NCCLS documents. Current editions are listed in the CLSI catalog, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org



Number 34

EP10-A3

Copyright [©]2006 Clinical and Laboratory Standards Institute. Except as stated below, neither this publication nor any portion thereof may be adapted, copied, or otherwise reproduced, by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from Clinical and Laboratory Standards Institute ("CLSI").

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, contact the Executive Vice President, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Suggested Citation

(Clinical and Laboratory Standards Institute. *Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline—Third Edition*. CLSI document EP10-A3 [ISBN 1-56238-622-0]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006.)

Proposed Guideline December 1985

Tentative Guideline June 1989

Tentative Guideline—Second Edition September 1993 **Approved Guideline** May 1998

Approved Guideline—Second Edition December 2002

Approved Guideline—Third Edition November 2006

ISBN 1-56238-622-0 ISSN 0273-3099

Volume 26

Committee Membership

Area Committee on Evaluation Protocols

Luann Ochs, MS Chairholder Roche Diagnostics Corporation Indianapolis, Indiana

Greg Cooper, CLS, MHA Vice-Chairholder Bio-Rad Laboratories, Inc., QSD Division Plano, Texas

George S. Cembrowski, MD, PhD Provincial Laboratory for Public Health Edmonton, Alberta, Canada

David L. Duewer, PhD National Institute of Standards and Technology Gaithersburg, Maryland

Anders Kallner, MD, PhD Karolinska Hospital Stockholm, Sweden

Kristian Linnet, MD, PhD University of Copenhagen Copenhagen, Denmark

Donald R. Parker, PhD Bayer HealthCare, LLC Elkhart, Indiana Daniel W. Tholen, MS American Association for Laboratory Accreditation Traverse City, Michigan

Lakshmi Vishnuvajjala, PhD FDA Ctr. for Devices/Rad. Health Rockville, Maryland

Advisors

David A. Armbruster, PhD, DABCC, FACB Abbott Laboratories Abbott Park, Illinois

R. Neill Carey, PhD Peninsula Regional Medical Center Salisbury, Maryland

Carl C. Garber, PhD, FACB Quest Diagnostics, Incorporated Lyndhurst, New Jersey

Patricia E. Garrett, PhD SeraCare Life Sciences, Inc. Portland, Maine

Martin H. Kroll, MD Dallas VA Medical Center Dallas, Texas Jan S. Krouwer, PhD Krouwer Consulting Sherborn, Massachusetts

Jacob (Jack) B. Levine, MBA Bayer Corporation Tarrytown, New York

EP10-A3

Donald M. Powers, PhD Powers Consulting Services Pittsford, New York

Max Robinowitz, MD FDA Ctr. for Devices/Rad. Health Rockville, Maryland

Gian Alfredo Scassellati, PhD Ente Nazional Italiano Di Unificatione Turin, Italy

Michele M. Schoonmaker, PhD Cepheid Sunnyvale, California

Jack Zakowski, PhD, FACB Beckman Coulter, Inc. Brea, California

Working Group on Evaluation of Quantitative Clinical Laboratory Methods

Jan S. Krouwer, PhD Chairholder Krouwer Consulting Sherborn, Massachusetts

George S. Cembrowski, MD, PhD Provincial Laboratory for Public Health Edmonton, Alberta, Canada Daniel W. Tholen, MS Dan Tholen Statistical Consulting Traverse City, Michigan

Staff

Clinical and Laboratory Standards Institute Wayne, Pennsylvania

John J. Zlockie, MBA Vice President, Standards Lois M. Schmidt, DA Staff Liaison

Patrice E. Polgar Projects Coordinator

Donna M. Wilhelm *Editor*

Melissa A. Lewis Assistant Editor

Acknowledgment

CLSI, the Area Committee on Evaluation Protocols, and the Working Group on Evaluation of Quantitative Clinical Laboratory Methods gratefully acknowledge Stanley Bauer, MD, a longtime contributor to CLSI, who had the foresight to commission Cuthbert Daniel, an award-winning statistical consultant, to prepare efficient protocols to evaluate commercial analyzers, and John Kennedy, also a dedicated contributor to CLSI, who chaired the original subcommittee that developed the EP10 consensus guideline.

Number 34

Volume 26	EP10-A3

Contents

Abstra	ct	i		
Committee Membershipiii				
Forewo	ord	vii		
Labora	tory Err	or Sources and CLSI Evaluation Protocols Documents viii		
1	Scope1			
2	Introduction1			
3	Standard Precautions1			
4	Terminology			
-	4.1	A Note on Terminology		
	4.2	Definitions		
5	Materia	als5		
	5.1	Reference Procedures		
6	Calibration and Sequence of Samples in a Run			
7	Number of Days and Runs			
8	Preliminary Procedures			
9	Collection and Recording of Data			
10	Initial Data Plotting and Inspection6			
	10.1 10.2 10.3	Difference Plot of Data vs. Concentration		
11	Analys	is of the Data for Imprecision9		
	11.1	Interpretation		
12	Prelim	inary Assessment of Bias10		
	12.1 12.2 12.3	Assigned Values		
13	Full Da	ata Analysis Procedures10		
	13.1 13.2	A Comment on the Model		
14	An Alternative Procedure			
15	Use of EP10 by Manufacturers11			
16	How to	Perform Multiple Regression for EP10 in Excel		

Number 34		

EP10-A3

Contents (Continued)

References	14
Symbols Used in Appendixes	15
Appendix A. Preliminary Performance Acceptability Check	16
Appendix B. Example Use of Data Sheets	22
Appendix C. Statistical Explanation	43
Summary of Consensus Comments and Committee Responses	46
Summary of Delegate Comments and Committee Responses	48
The Quality System Approach	50
Evaluation Protocols Documents, Descriptions, and Key Words	51

Volume 26

Foreword

Before using a new measurement procedure or instrument for *in vitro* diagnostic use, the laboratory must make a preliminary decision about its acceptability. This initial performance check is neither a rigorous characterization of long-term performance nor an evaluation of the many factors that can affect results produced by the device. Rather, this experiment is a quick check to rule out major problems and a starting point for accumulating data and experience that will enable the user to make a final decision. The primary purpose of this document is to help detect performance problems that would warrant immediate correction, referral to the manufacturer, or expanded investigation before a new device is placed into service.

This document may also now be used by manufacturers to either establish the magnitude of factors that can affect performance or verify that such magnitude is acceptable.

Additional revisions since the last edition of EP10 (2002) include:

- a figure to illustrate which error sources the EP10 protocol can detect with respect to all error sources and other EP documents (see page viii);
- suggested sample sizes, so now the document is useful for manufacturers;
- instructions for the multiple regression calculations in Excel;
- revised references; and
- revised definitions.

Key Words


Carry-over, comparison of methods, drift, evaluation protocol, experimental design, linearity, multiple regression, outlier, precision

EP10-A3

Number 34

EP10-A3

Laboratory Error Sources and CLSI Evaluation Protocols Documents



Laboratory Error Sources and CLSI Evaluation Protocols Documents.^a This figure illustrates the relationship among parameters estimated by EP documents. Items higher up in the figure are more comprehensive whereas lower level items are more specific. Overall, the figure is much like a cause-and-effect diagram. Documents marked (d) provide guidance for demonstrating that a source of measurement inaccuracy is within acceptable limits. Documents marked (v) provide guidance for more rigorous evaluation of inaccuracy components.

^a For a description of each of the documents listed, please see page 53.

Volume 26

Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline—Third Edition

1 Scope

Before starting a complete evaluation of a new measurement procedure, kit, or instrument for *in vitro* diagnostic use, it is often necessary to make a preliminary decision about its acceptability. This initial performance check is neither a rigorous investigation into the procedure's long-term performance, nor an evaluation of the many factors that can affect results produced by the device. The primary purpose of this document is to help detect problems that are severe enough to warrant immediate correction, referral to the manufacturer, or expanded investigation. Accreditation bodies may have requirements for verification or validation that exceed the procedures in this document (see the most current edition of CLSI document EP15—*User Verification of Performance for Precision and Trueness*).

Manufacturers can also benefit by performing this protocol either as assays are developed or when they are validated. By performing more than five runs, manufacturers can detect trends in the effects estimated by EP10 or document their absence.

2 Introduction

This document describes a procedure for the preliminary evaluation of linearity, proportional and constant bias, linear drift, sample carry-over, and precision of a clinical laboratory measurement procedure. Preliminary evaluations should be performed before new procedures are used to test patients' samples and when any modifications of procedures are made. This guideline is based on a protocol and procedure developed for continuous flow analyzers.¹ The rationale for recommending a protocol based on so old a system is explained in Section 13.1. The experiment is intended primarily for evaluating automated instruments but may be appropriate for kits, manual procedures, or other *in vitro* diagnostic devices. By repeating a sequence of only ten samples, performance characteristics may be evaluated by plotting the data and performing some simple calculations. Using a statistical technique called multiple linear regression analysis, further information about the factors influencing accuracy (such as sample carry-over linear drift, and nonlinearity) can be obtained. Instructions are given for simple data analysis, in case a computer is not available.

The experiment is intended to provide preliminary estimates of those performance characteristics that may be used to determine the ultimate acceptability of the device. The results should be used only to determine whether the device has grossly unacceptable performance.

The following sections outline the materials and procedures to be used. Many variations on this basic experiment are possible (such as extending the number of days or eliminating the priming samples when appropriate). Variations should be dictated by the complexities of the device, the particular characteristics of the measurement procedure, and the resources available to the user.

3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to "standard precautions." Standard precautions are guidelines that combine the major features of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (Garner JS, Hospital Infection Control Practices Advisory Committee.